View Item 

Show simple item record

Metformin; a review of its history and future: from lilac to longevity
dc.contributor.authorThomas, Inas
dc.contributor.authorGregg, Brigid
dc.date.accessioned2017-01-10T19:08:44Z
dc.date.available2018-04-02T18:03:23Zen
dc.date.issued2017-02
dc.identifier.citationThomas, Inas; Gregg, Brigid (2017). "Metformin; a review of its history and future: from lilac to longevity." Pediatric Diabetes 18(1): 10-16.
dc.identifier.issn1399-543X
dc.identifier.issn1399-5448
dc.identifier.urihttps://hdl.handle.net/2027.42/135516
dc.publisherJohn Wiley & Sons A/S
dc.subject.othermetformin
dc.subject.otherpediatrics
dc.subject.othermechanisms
dc.subject.otherdiabetes
dc.titleMetformin; a review of its history and future: from lilac to longevity
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPediatrics
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/135516/1/pedi12473_am.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/135516/2/pedi12473.pdf
dc.identifier.doi10.1111/pedi.12473
dc.identifier.sourcePediatric Diabetes
dc.identifier.citedreferenceLavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011; 305 ( 16 ): 1659 ‐ 1668.
dc.identifier.citedreferenceIbanez L, Lopez‐Bermejo A, Diaz M, Marcos MV, de Zegher F. Pubertal metformin therapy to reduce total, visceral, and hepatic adiposity. J Pediatr. 2010; 156 ( 1 ): 98 ‐ 102.
dc.identifier.citedreferenceGenerali JA, Cada DJ. Metformin: prevention and treatment of antipsychotic‐induced weight gain. Hosp Pharm. 2013; 48 ( 9 ): 734 ‐ 777.
dc.identifier.citedreferenceShiasi Arani K, Taghavi Ardakani A, Moazami Goudarzi R, et al. Effect of vitamin E and metformin on fatty liver disease in obese children‐ randomized clinical trial. Iran J Public Health. 2014; 43 ( 10 ): 1417 ‐ 1423.
dc.identifier.citedreferenceNimako GK, Wintrob ZA, Sulik DA, Donato JL, Ceacareanu AC. Synergistic benefit of statin and metformin in gastrointestinal malignancies. J Pharm Pract. 2016. pii: 0897190015627255
dc.identifier.citedreferenceKordes S, Pollak MN, Zwinderman AH, et al. Metformin in patients with advanced pancreatic cancer: a double‐blind, randomised, placebo‐controlled phase 2 trial. Lancet Oncol. 2015; 16 ( 7 ): 839 ‐ 847.
dc.identifier.citedreferencePernicova I, Korbonits M. Metformin‐‐mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol. 2014; 10 ( 3 ): 143 ‐ 156.
dc.identifier.citedreferenceButalia S, Gutierrez L, Lodha A, Aitken E, Zakariasen A, Donovan L. Short‐ and long‐term outcomes of metformin compared with insulin alone in pregnancy: a systematic review and meta‐analysis. Diabet Med. 2016. DOI: 10.1111/dme.13150
dc.identifier.citedreferenceBlandino G, Valerio M, Cioce M, et al. Metformin elicits anticancer effects through the sequential modulation of DICER and c‐MYC. Nat Commun. 2012; 3: 865.
dc.identifier.citedreferenceRowan JA, Rush EC, Obolonkin V, Battin M, Wouldes T, Hague WM. Metformin in gestational diabetes: the offspring follow‐up (MiG TOFU): body composition at 2 years of age. Diabetes Care. 2011; 34 ( 10 ): 2279 ‐ 2284.
dc.identifier.citedreferenceDadwal P, Mahmud N, Sinai L, et al. Activating endogenous neural precursor cells using metformin leads to neural repair and functional recovery in a model of childhood brain injury. Stem Cell Reports. 2015; 5 ( 2 ): 166 ‐ 173.
dc.identifier.citedreferenceHafner P, Bonati U, Rubino D, et al. Treatment with L‐citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single‐centre, randomised, placebo‐controlled trial. Trials. 2016; 17 ( 1 ): 389.
dc.identifier.citedreferenceFDA Drug Safety Communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function. http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm. Accessed June 10, 2016.
dc.identifier.citedreferenceSakoda LC, Ferrara A, Achacoso NS, et al. Metformin use and lung cancer risk in patients with diabetes. Cancer Prev Res (Phila). 2015; 8 ( 2 ): 174 ‐ 179.
dc.identifier.citedreferenceLexicomp Online [database on the Internet]. Wolters Kluwer. Accessed: August 14, 2016.
dc.identifier.citedreferenceDeFronzo RA, Buse JB, Kim T, et al. Once‐daily delayed‐release metformin lowers plasma glucose and enhances fasting and postprandial GLP‐1 and PYY: results from two randomised trials. Diabetologia. 2016; 59: 1645 ‐ 54.
dc.identifier.citedreferenceAbdemur A, Han SM, Lo Menzo E, Szomstein S, Rosenthal R. Reasons and outcomes of conversion of laparoscopic sleeve gastrectomy to Roux‐en‐Y gastric bypass for nonresponders. Surg Obes Relat Dis. 2016; 12 ( 1 ): 113 ‐ 118.
dc.identifier.citedreferenceSrinivasan S, Florez JC. Therapeutic challenges in diabetes prevention: we have not found the "exercise pill". Clin Pharmacol Ther. 2015; 98 ( 2 ): 162 ‐ 169.
dc.identifier.citedreferenceHe L, Meng S, Germain‐Lee EL, Radovick S, Wondisford FE. Potential biomarker of metformin action. J Endocrinol. 2014; 221 ( 3 ): 363 ‐ 369.
dc.identifier.citedreferenceBailey CJ, Day C. Traditional plant medicines as treatments for diabetes. Diabetes Care. 1989; 12 ( 8 ): 553 ‐ 564.
dc.identifier.citedreferencePryor R, Cabreiro F. Repurposing metformin: an old drug with new tricks in its binding pockets. Biochem J. 2015; 471 ( 3 ): 307 ‐ 322.
dc.identifier.citedreferenceHowlett HC, Bailey CJ. A risk‐benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf. 1999; 20 ( 6 ): 489 ‐ 503.
dc.identifier.citedreferenceStang M, Wysowski DK, Butler‐Jones D. Incidence of lactic acidosis in metformin users. Diabetes Care. 1999; 22 ( 6 ): 925 ‐ 927.
dc.identifier.citedreferenceInzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 2002; 287 ( 3 ): 360 ‐ 372.
dc.identifier.citedreferenceNathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32 ( 1 ): 193 ‐ 203.
dc.identifier.citedreferenceIMS Institute for Healthcare Informatics. The Use of Medicines in the United States: Review of 2010. IMSHealth.com. Accessed June 10, 2016.
dc.identifier.citedreferenceTodd JN, Florez JC. An update on the pharmacogenomics of metformin: progress, problems and potential. Pharmacogenomics. 2014; 15 ( 4 ): 529 ‐ 539.
dc.identifier.citedreferencePawlyk AC, Giacomini KM, McKeon C, Shuldiner AR, Florez JC. Metformin pharmacogenomics: current status and future directions. Diabetes. 2014; 63 ( 8 ): 2590 ‐ 2599.
dc.identifier.citedreferenceBo QJ, Wang ZM, Li XB, Ma X, Wang CY, de Leon J. Adjunctive metformin for antipsychotic‐induced hyperprolactinemia: a systematic review. Psychiatry Res. 2016; 237: 257 ‐ 263.
dc.identifier.citedreferenceEl‐Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000; 275 ( 1 ): 223 ‐ 228.
dc.identifier.citedreferenceMiller RA, Birnbaum MJ. An energetic tale of AMPK‐independent effects of metformin. J Clin Invest. 2010; 120 ( 7 ): 2267 ‐ 2270.
dc.identifier.citedreferencePerriello G, Misericordia P, Volpi E, et al. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes. 1994; 43 ( 7 ): 920 ‐ 928.
dc.identifier.citedreferenceStumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non‐insulin‐dependent diabetes mellitus. N Engl J Med. 1995; 333 ( 9 ): 550 ‐ 554.
dc.identifier.citedreferenceMiller RA, Chu Q, Xie J, Foretz M, Viollet B, Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature. 2013; 494 ( 7436 ): 256 ‐ 260.
dc.identifier.citedreferenceMadiraju AK, Erion DM, Rahimi Y, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature. 2014; 510 ( 7506 ): 542 ‐ 546.
dc.identifier.citedreferenceBailey CJ, Puah JA. Effect of metformin on glucose metabolism in mouse soleus muscle. Diabete Metab. 1986; 12 ( 4 ): 212 ‐ 218.
dc.identifier.citedreferenceMusi N, Hirshman MF, Nygren J, et al. Metformin increases AMP‐activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes. 2002; 51 ( 7 ): 2074 ‐ 2081.
dc.identifier.citedreferenceRossetti L, DeFronzo RA, Gherzi R, et al. Effect of metformin treatment on insulin action in diabetic rats: in vivo and in vitro correlations. Metabolism. 1990; 39 ( 4 ): 425 ‐ 435.
dc.identifier.citedreferenceKirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002; 137 ( 1 ): 25 ‐ 33.
dc.identifier.citedreferenceForetz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab. 2014; 20 ( 6 ): 953 ‐ 966.
dc.identifier.citedreferenceForslund K, Hildebrand F, Nielsen T, et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature. 2015; 528 ( 7581 ): 262 ‐ 266.
dc.identifier.citedreferenceMaida A, Lamont BJ, Cao X, Drucker DJ. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator‐activated receptor‐alpha in mice. Diabetologia. 2011; 54 ( 2 ): 339 ‐ 349.
dc.identifier.citedreferenceBahne E, Hansen M, Bronden A, Sonne DP, Vilsboll T, Knop FK. Involvement of glucagon‐like peptide‐1 in the glucose‐lowering effect of metformin. Diabetes Obes Metab. 2016; 18: 955 ‐ 961.
dc.identifier.citedreferenceBrufani C, Fintini D, Nobili V, Patera PI, Cappa M, Brufani M. Use of metformin in pediatric age. Pediatr Diabetes. 2011; 12 ( 6 ): 580 ‐ 588.
dc.identifier.citedreferenceDiabetes Prevention Program Research Group. Long‐term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15‐year follow‐up: the Diabetes Prevention Program Outcomes Study. Lancet Diabetes Endocrinol. 2015; 3 ( 11 ): 866 ‐ 875.
dc.identifier.citedreferenceKnowler WC, Barrett‐Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346 ( 6 ): 393 ‐ 403.
dc.identifier.citedreferenceProduct Information: GLUCOPHAGE(R), GLUCOPHAGE(R)XR oral tablets, extended‐release oral tablets, metformin hydrochloride oral tablets, extended‐release oral tablets. Bristol‐Myers Squibb Company, Princeton, NJ 2009
dc.identifier.citedreferenceNadeau KJ, Chow K, Alam S, et al. Effects of low dose metformin in adolescents with type I diabetes mellitus: a randomized, double‐blinded placebo‐controlled study. Pediatr Diabetes. 2015; 16 ( 3 ): 196 ‐ 203.
dc.identifier.citedreferenceLibman IM, Miller KM, DiMeglio LA, et al. Effect of metformin added to insulin on glycemic control among overweight/obese adolescents with type 1 diabetes: a randomized clinical trial. JAMA. 2015; 314 ( 21 ): 2241 ‐ 2250.
dc.identifier.citedreferenceEvans JM, Doney AS, AlZadjali MA, et al. Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am J Cardiol. 2010; 106 ( 7 ): 1006 ‐ 1010.
dc.identifier.citedreferenceBacha F, Klinepeter Bartz S. Insulin resistance, role of metformin and other non‐insulin therapies in pediatric type 1 diabetes. Pediatr Diabetes. 2015; 17: 545 ‐ 558.
dc.identifier.citedreferenceDomecq JP, Prutsky G, Leppin A, et al. Clinical review: drugs commonly associated with weight change: a systematic review and meta‐analysis. J Clin Endocrinol Metab. 2015; 100 ( 2 ): 363 ‐ 370.
dc.identifier.citedreferenceBouza C, Lopez‐Cuadrado T, Gutierrez‐Torres LF, Amate J. Efficacy and safety of metformin for treatment of overweight and obesity in adolescents: an updated systematic review and meta‐analysis. Obes Facts. 2012; 5 ( 5 ): 753 ‐ 765.
dc.identifier.citedreferenceWilson DM, Abrams SH, Aye T, et al. Metformin extended release treatment of adolescent obesity: a 48‐week randomized, double‐blind, placebo‐controlled trial with 48‐week follow‐up. Arch Pediatr Adolesc Med. 2010; 164 ( 2 ): 116 ‐ 123.
dc.identifier.citedreferenceKnowler WC, Fowler SE, Hamman RF, et al. 10‐year follow‐up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009; 374: 1677 ‐ 1186.
dc.identifier.citedreferenceCadeddu C, Nocco S, Cugusi L, et al. Effects of metformin and exercise training, alone or in combination, on cardiac function in individuals with insulin resistance. Cardiol Ther. 2016; 5: 63 ‐ 73.
dc.identifier.citedreferenceTODAY Study Group. Lipid and inflammatory cardiovascular risk worsens over 3 years in youth with type 2 diabetes: the TODAY clinical trial. Diabetes Care. 2013; 36 ( 6 ): 1758 ‐ 1764.
dc.identifier.citedreferenceKuzik N, Myette‐Cote E, Carson V, Slater L, Boule NG. Evaluating the effects of metformin use on height in children and adolescents: a meta‐analysis of randomized clinical trials. JAMA Pediatr. 2015; 169 ( 11 ): 1032 ‐ 1039.
dc.identifier.citedreferenceStroescu R, Micle I, Bizerea T, Puiu M, Marginean O, Doros G. Metabolic monitoring of obese children born small for gestational age. Obes Res Clin Pract. 2014; 8 ( 6 ): e592 ‐ e598.
dc.identifier.citedreferenceDiaz M, Bassols J, Lopez‐Bermejo A, de Zegher F, Ibanez L. Metformin treatment to reduce central adiposity after prenatal growth restraint: a placebo‐controlled pilot study in prepubertal children. Pediatr Diabetes. 2015; 16 ( 7 ): 538 ‐ 545.
dc.identifier.citedreferenceIbanez L, Lopez‐Bermejo A, Diaz M, Marcos MV, de Zegher F. Metformin treatment for four years to reduce total and visceral fat in low birth weight girls with precocious pubarche. J Clin Endocrinol Metab. 2008; 93 ( 5 ): 1841 ‐ 1845, DOI: 10.1210/jc.2008‐0013.
dc.identifier.citedreferenceIbanez L, Ong K, Valls C, Marcos MV, Dunger DB, de Zegher F. Metformin treatment to prevent early puberty in girls with precocious pubarche. J Clin Endocrinol Metab. 2006; 91 ( 8 ): 2888 ‐ 2891.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
pedi12473_am.pdf
Size:
602.7KB
Format:
PDF
View/Open
Name:
pedi12473.pdf
Size:
782.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.